Literature DB >> 21807747

Editorial: CD38 and retinoids: a step toward a cure.

Fabio Malavasi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21807747     DOI： 10.1189/jlb.0211069

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


× No keyword cloud information.
  7 in total

1.  Phosphorylation of c-Cbl and p85 PI3K driven by all-trans retinoic acid and CD38 depends on Lyn kinase activity.

Authors:  Johanna Congleton; Miaoqing Shen; Robert MacDonald; Fabio Malavasi; Andrew Yen
Journal:  Cell Signal       Date:  2014-03-29       Impact factor: 4.315

2.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Authors:  I S Nijhof; R W J Groen; H M Lokhorst; B van Kessel; A C Bloem; J van Velzen; R de Jong-Korlaar; H Yuan; W A Noort; S K Klein; A C M Martens; P Doshi; K Sasser; T Mutis; N W C J van de Donk
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

Review 3.  Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.

Authors:  Salma Afifi; Angela Michael; Alexander Lesokhin
Journal:  Ann Pharmacother       Date:  2016-04-15       Impact factor: 3.154

Review 4.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

Review 5.  CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

Authors:  Niels W C J van de Donk; Saad Z Usmani
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

Review 6.  The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Morandi; Cristiano Bracci; Francesco Lanza; Nicola Giuliani; Aneel Paulus; Fabio Malavasi
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

7.  Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Authors:  Estefanía García-Guerrero; Ralph Götz; Sören Doose; Markus Sauer; Alfonso Rodríguez-Gil; Thomas Nerreter; K Martin Kortüm; José A Pérez-Simón; Hermann Einsele; Michael Hudecek; Sophia Danhof
Journal:  Leukemia       Date:  2020-04-29       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.